MM logo
This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner. Read More ›

Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy. Read More ›

A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›

Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM. Read More ›

Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment. Read More ›

Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone. Read More ›

Results from the IFM2017-03 trial showed that a dexamethasone-sparing regimen of daratumumab (Darzalex) plus lenalidomide (Revlimid; DR) was superior to lenalidomide plus dexamethasone (Rd) in terms of response rates and rates of minimal residual disease (MRD) negativity in frail patients with newly diagnosed multiple myeloma. Read More ›

On October 25, 2022, the FDA accelerated the approval of teclistamab-cqyv (Tecvayli; Janssen Biotech), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who received ≥4 previous lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. Read More ›

Data from the IMAGE study support real-world use of isatuximab in patients with relapsed/refractory multiple myeloma, with findings similar to those reported for ICARIA-MM. Read More ›

Patient-reported outcomes with ciltacabtagene autoleucel are consistent with clinical findings and support its use in heavily pretreated patients with relapsed/refractory multiple myeloma. Read More ›

Page 1 of 13

© Amplity Health. All Rights Reserved. Privacy Policy.